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Abstract
Genistein has been shown to suppress the growth of several cancers through modulation of various pathways. However,
the effects of genistein on the regulation of oncogenic microRNA-151 (miR-151) have not been reported. In this study, we
investigated whether genistein could alter the expression of oncogenic miR-151 and its target genes that are involved in the
progression and metastasis of prostate cancer (PCa). Real-time RT-PCR showed that the expression of miR-151 was higher in
PC3 and DU145 cells compared with RWPE-1 cells. Treatment of PC3 and DU145 cells with 25 mM genistein down-regulated
the expression of miR-151 compared with vehicle control. Inhibition of miR-151 in PCa cells by genistein significantly
inhibited cell migration and invasion. In-silico analysis showed that several genes (CASZ1, IL1RAPL1, SOX17, N4BP1 and
ARHGDIA) suggested to have tumor suppressive functions were target genes of miR-151. Luciferase reporter assays
indicated that miR-151 directly binds to specific sites on the 39UTR of target genes. Quantitative real-time PCR analysis
showed that the mRNA expression levels of the five target genes in PC3 and DU145 were markedly changed with miR-151
mimics and inhibitor. Kaplan-Meier curves and log-rank tests revealed that high expression levels of miR-151 had an adverse
effect on survival rate. This study suggests that genistein mediated suppression of oncogenic miRNAs can be an important
dietary therapeutic strategy for the treatment of PCa.
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Introduction
Prostate cancer (PCa) is one of the most common malignancies
among men and ranks second to lung cancer in cancer-related
deaths [1]. After androgen-deprivation therapy. PCa may most
recur as androgen-independent, metastatic disease that leads to
death within several years [2]. Currently, no effective therapies are
available to cure androgen-independent PCa. Thus, new prognos-
tic markers and effective treatment strategies are urgently needed.
MicroRNAs (miRNAs) are a class of small non-coding RNA of
approximately 22 nucleotides that regulate gene expression
through translational repression and mRNA cleavage [3].
Bioinformatics indicate that miRNAs regulate 60% of protein-
coding genes [4]. At present, 1,527 human miRNAs have been
registered in the miRBase database (http://microrna.sanger.ac.
uk/). miRNAs are involved in a variety of biological processes,
including metabolism, development, and differentiation, and
contribute to the development of various types of cancer [5].
Many human cancers have aberrant expression of miRNAs, which
can function either as tumor suppressors or oncogenes [6].
miR-151 is mapped to a region of chromosome 8q. That has
been found to be frequently amplified in several cancers including
bladder, kidney, prostate, breast, lung, gastric and rectal cancer
[7–13]. We previously demonstrated that chromosomal gain of
locus 8q24.3, where oncogenic LY6K gene resides, may have
a critical role in bladder cancer development [7]. One paper
showed that copy number gain of the miR-151 gene at 8q24.3 in
PCa was correlated with metastasis [14].
Genistein (49,5,7-Trihydroxyisoflavone), a major isoflavone
constituent of soybeans and soy products, has been shown to
exhibit potent anticancer effects on PCa [15,16]. Epidemiological
evidence indicate that the incidence and mortality rates of PCa are
considerably lower in Asia compared to the United States [17].
The mean serum concentration of genistein in Asian men was
higher than that of the US population [18] and several studies
have demonstrated that isoflavone intake was associated with
a reduction in PCa risk [19–22]. Genistein has multiple molecular
targets including receptors, enzymes, and signaling pathways [15].
Genistein has also been shown to suppress the growth of several
cancer cell lines in vitro and in vivo, reducing the expression of
several oncogenic miRNAs. To date, the effects of genistein on the
regulation of miR-151 have not been reported. Therefore in this
study we investigated whether genistein could alter the expression
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of miR-151 and its target genes involved in the progression and
metastasis of PCa.
Results
miR-151 is Up-regulated in PCa and Genistein Treatment
Decreased miR-151
To determine relative expression levels of miR-151 in PCa cells,
we performed TaqMan quantitative real-time PCR analysis using
androgen-dependent (LNCaP) and androgen-independent (PC3,
DU145) cell lines and compared these with normal prostate
epithelial cells (RWPE-1). miR-151 consists of two mature
miRNAs; miR-151a-5p and miR-151a-3p (miRBase). We ob-
served that miR-151 expression was markedly up-regulated in
androgen-independent PCa cell lines compared to RWPE-1 cells
(miR-151a-5p; PC3 4.02-fold, DU145 1.36-fold) (miR-151a-3p;
PC3 5.14-fold, DU145 2.25-fold) (Fig. 1A).
Genistein treatment significantly down-regulated the relative
expression level of miR-151 compared with vehicle control (miR-
151a-5p; PC3 15% decrease, DU145 14% decrease) (miR-151a-
3p; PC3 44% decrease, DU145 32% decrease) (Fig. 1B).
Effect of miR-151 Knockdown on Cell Proliferation,
Migration, and Invasion in PCa Cell Lines
To examine the functional roles of miR-151, we performed loss-
of-function studies using anti-miR miRNA inhibitor transfected
into PC3 and DU145 cells. The expression of miR-151 was
markedly repressed in anti-miR miRNA inhibitor transfectants
(data not shown) and we observed similar cell viability in all cell
lines, suggesting that knockdown miR-151 did not affect cell
proliferation (data not shown). Wound healing assay demonstrated
significant inhibition of cell migration in anti-miR miRNA-151a-
5p transfected PCa cell lines compared with their counterparts
(Fig. 2A). However, no significant inhibition was observed with
anti-miR miRNA-151a-3p transfected PCa cell lines. The
Figure 1. Expression of miR-151 in PCa cells and effect of genistein treatment. (A) Expression profile of miR-151 in PCa cell lines (LNCaP,
DU145 and PC3) and normal prostate epithelial cells (RWPE-1). Real-time PCR showed that the expression levels of miR-151 were up-regulated in
androgen-independent PCa cell lines (DU145 and PC3). miR-151 expression was normalized to RNU48. Data are presented as means 6 SE. (B)
Expression levels of miR-151 after treatment with genistein (25 mM). miR-151 expression was found to be reduced by 15–45% in genistein treated
cells. *,P,0.05.
doi:10.1371/journal.pone.0043812.g001
Figure 2. Effect of miR-151a-5p knockdown on prostate cancer cell migration and invasion. (A) Knockdown of miR-151a-5p significantly
inhibits cell migration. After transfection (48 hours), a wound was formed by scraping and the wound measured after 24 hours. Representative
images of wound healing assay are shown at x200 magnification. **,P,0.0001 (B) Knockdown of miR-151a-5p significantly decreased cell invasion.
Representative images of invasion assay are shown at x200 magnification. **,P,0.0001.
doi:10.1371/journal.pone.0043812.g002
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Matrigel invasion assay demonstrated that the number of invading
cells was significantly decreased in anti-miR miRNA-151a-5p
transfectants compared with their counterparts (Fig. 2B). There-
fore it is likely that miR-151a-5p plays on important role in tumor
cell migration and invasion. To evaluate the simultaneous effects
of miR-151a-5p and miR-151a-3p, loss-of-function studies using
miRNA inhibitor co-transfected PCa cell lines was carried out.
There was no additional effect on cell viability by miR-151a-5p
and miR-151a-3p co-transfection (data not shown).
Identification of miR-151a-5p Target Genes by In-silico
Analysis
To identify potential target genes of miR-151a-5p, we used
TargetScan and microRNA.org to identify sites where these
miRNAs bind. These programs identified five genes containing
putative target sites for miR-151a-5p in their 39UTR (N4BP1:
NEDD4 binding protein 1, CASZ1: castor zinc finger 1,
IL1RAPL1: interleukin 1 receptor accessory protein-like 1,
SOX17: SRY (sex determining region Y)-box 17 and ARHGDIA:
Rho GDP dissociation inhibitor (GDI) alpha. These genes were
identified by both algorithms and bioinformatic analysis showed
they may have tumor suppressor function in several cancers [23–
27].
Luciferase Reporter Assays Using Vectors Containing
39UTR Binding Sites of Putative Target Genes
CASZ1, IL1RAPL1 and ARHGDIA each have one predicted
binding site for miR-151a-5p in their 39UTRs while N4BP1 and
SOX17 each have two predicted binding sites (Fig. 3). We cloned
the putative miR-151a-5p 39UTRs targets into a luciferase
reporter assay vector. Luciferase reporter assay demonstrated that
miR-151a-5p decreased the relative luciferase activities of CASZ1,
IL1RAPL1 and ARHGDIA (Fig. 4A, 4B and 4E). Luciferase
reporter assay also demonstrated that suppression of miR-151a-5p
increased the relative luciferase 39UTR activities. Mutation of the
putative miR-151a-5p binding sites in these 39UTRs decreased the
response to miR-151a-5p. These results indicate that miR-151a-5p
binds directly to the 39UTRs of CASZ1, IL1RAPL1 and
Figure 3. Putative miR-151a-5p binding and mutated sites in the 39UTR of target genes.
doi:10.1371/journal.pone.0043812.g003
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ARHGDIA. Luciferase reporter assay also demonstrated that
miR-151a-5p decreased the relative luciferase activities, and
knockdown of miR-151a-5p increased the relative luciferase
activities with both wild-type SOX17 39UTRs (Position 472–478
and Position 769–776) (Fig. 4C and 4D). N4BP1 39UTR Position
3383–3389 showed no luciferase activity change with either miR-
151a-5p mimics or miR-151a-5p inhibitor. The other target site
(Position 4077–4083) showed that miR-151a-5p markedly de-
creased the relative luciferase activity and suppression of miR-
151a-5p significantly increased luciferase activity with the wild-
type 39UTR. Thus these data suggest that miR-151a-5p directly
binds to one site (Position 4077–4083) on the 39UTR of N4BP1
mRNA.
Regulation of Target Gene Expression in PCa Cell Lines by
miR-151a-5p
Quantitative real-time PCR analysis showed that the mRNA
expression levels of the five target genes in PC3 and DU145 were
markedly repressed in the miR-151a-5p transfectants compared
with the controls (Fig. 5A–E). In addition, mRNA expression of
the five target genes in PC3 and DU145 were markedly up-
regulated in the miR-151a-5p inhibitor transfectants compared
with the controls. We also evaluated the effects of genistein on the
mRNA expression of miR-151a-5p targets. These target genes
were almost up-regulated with genistein treatment in DU145 cell
lines (Fig. 5F). The protein expression levels of SOX17 and
ARHGDIA were significantly decreased in the miR-151a-5p
transfectants compared with the controls and up-regulated in the
miR-151a-5p inhibitor transfectants (Fig. 5G).
Up-regulated Expression of miR-151-5p in PCa
Specimens
We evaluated expression levels of miR-151-5p in PCa (n = 30)
and benign prostate cancer (BPH) (n = 17) tissues. The expression
levels of miR-151-5p were significantly higher in PCa compared
with BPH tissues (P = 0.0001; Fig. 6A). To determine if the levels
of miR-151a-5p in tumor tissues correlates with survival of the
PCa patients, we also measured miR-151a-5p expression levels in
human tumor samples (Fig. 6B). The results show that patients
with high miR-151a-5p expression had a lower survival rate than
those with low 151a-5p expression, though these results did not
reach statistical significance (P = 0.0944). There was also no
significant correlation with another clinico-pathological factors
(tumor stage and Gleason Score) (data not shown).
Discussion
In this study we have demonstrated that the miR-151 is highly
expressed in androgen-independent PCa cell lines and that cell
motility and invasiveness are reduced in miR-151a-5p knockdown
cell lines (PC3 and DU145). miR-151 consists of two mature
miRNAs; miR-151a-5p and miR-151a-3p. Two mature miRNAs
are excised from the same stem-loop precursor-miR-151a. Thus
miR-151a-5p and miR-151a-3p have different sequences and
therefore target different mRNAs. Wound healing assay and
invasion assay demonstrated that knockdown of miR-151a-5p, but
not miR-151a-3p, significantly decreased PCa cell migration and
invasion. These results suggest that miR-151a-5p functions as an
oncogene by increasing cell migration and invasion in PCa. In
contrast, there was no significant effect on cell proliferation in
miR-151a-5p inhibitor transfected PCa cells, suggesting that miR-
151a-5p is not involved in proliferation activity. In this study, we
showed that up-regulation of miR-151a-5p expression in tumors is
related to lower survival of PCa patients however these results
were not significantly different with either this parameter or other
clinic-pathological features. Since our cohort was not large (n = 30)
and included only five samples of advanced cancer (more than
pT3) and three samples with a Gleason Score of 8 or more, studies
on a larger number of samples with a balanced pathological
background will have to be conducted for more precise statistical
evaluation.
Computational bioinformatics and 39 luciferase reporter assays
indicate that miR-151a-5p has several potential target genes
(CASZ1, IL1RAPL1, SOX17, N4BP1 and ARHGDIA). CASZ1,
a neuronal differentiation gene, have been shown to possess tumor
suppressor activity. In clinical primary tumor sumples, the
expression of CASZ1 is significantly decreased in aggressive
neuroblastoma compared with the favorable tumors [28]. The
restoration of CASZ1 expression inhibits tumor migration in vitro
and suppressed tumorigenicity in vivo [23]. The IL1RAPL1 gene is
located at a region on chromosome X and the protein encoded by
this gene is a member of the interleukin 1 receptor family and is
similar to interleukin 1 accessory proteins [29]. IL1RAPL1 has
been reported to be downregulated in many brain tumor cell lines
and xenografts compared with normal tissues [24] suggesting that
it may function as a tumor suppressor [30]. The SOX17 gene
encodes a member of the SOX family of transcription factors
involved in the regulation of embryonic development and in the
determination of the cell fate [31]. Real time quantitative PCR
showed that SOX17 expression was lower in gastric cancer tissues
than those in normal tissues [32]. SOX17 was reported to be
a candidate tumor suppressor gene that inhibits the canonical
WNT/b-catenin signaling pathway in colorectal cancer and
hepatocellular carcinoma [25,33]. N4BP1 has been identified as
a substrate for mono ubiquitylation by E3 ubiquitin ligase Nedd4
[34]. It has been shown that N4BP1 interacts with and negatively
regulates ITCH E3 activity directed toward its substrates including
c-Jun and p53-related tumor suppressor proteins (p73 and p63)
[35]. ARHGDIA is a cellular regulatory protein that binds to and
negatively regulates most Rho GTPases including RhoA, Rac1,
and Cdc42 [36]. Loss of ARHGDIA enhances metastasis and
resistance to tamoxifen in breast cancer [37] and loss of
ARHGDIA expression promotes the development and progression
of PCa [27]. In thisb study we showed that the mRNA expression
levels of these five tumor suppressor target genes in PC3 and
DU145 were markedly changed in experimentation with miR-
151a-5p mimics and miR-151a-5p inhibitor, indicating that miR-
151-5p directly targets these genes.
Genistein has been shown to suppress the growth of several
cancer cell lines in vitro and in vivo, reducing the expression of
oncogenic miRNAs, such as miR-21 [38], miR-27a [39], miR-221
and miR-222 [40]. In this study, we showed that genistein
treatment significantly down-regulated the relative expression level
of oncogenic miR-151. Recently, our group showed that genistein
inhibited the expression of miR-21 in kidney cancer cells and in
the tumors formed after injecting genistein treated kidney cancer
Figure 4. Luciferase reporter assays using the vectors encoding putative target sites of 39UTR. PC-3 cells were transiently transfected
with Pre-miR miRNA precursor or Anti-miR miRNA Inhibitor or negative control, followed by transient transfection with wild-type 39UTR reporter
plasmids or mutated 39UTR plasmids for 24 hours. 39UTR reporter activity was measured by luciferase assay and normalized to activity of Renilla
luciferase. Data are presented as the mean 6 SE. *,P,0.05.
doi:10.1371/journal.pone.0043812.g004
Genistein Suppresses PCa by Inhibition of MiR-151
PLOS ONE | www.plosone.org 5 August 2012 | Volume 7 | Issue 8 | e43812
Genistein Suppresses PCa by Inhibition of MiR-151
PLOS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e43812
cells in nude mice along with inhibition of tumor formation [38].
miR-27a has been reported to be a oncogenic miRNA in various
cancer cells, and its expression and target gene (ZBTB10) levels
were dependent on the dose of genistein [39]. We have previously
demonstrated that genistein upregulated tumor suppressor gene
ARHI by downregulating miR-221 and miR-222 in PCa [40].
Genistein also has been reported to suppress the growth of several
cancers by increasing the expression of the tumor suppressors,
miR-146a [41] and miR-1296 [42]. Treatment of pancreatic
cancer cells with isoflavone compounds (including 70.54%
genistein), increased miR-146a expression, causing downregula-
tion of EGFR, MTA-2, IRAK-1, and NF-kB, resulted in
inhibition of cell invasion [41]. We have also reported that
genistein increased miR-1296 expression (3 to 5-fold) in PCa cells
and significantly downregulated the expression of MCM2 which is
target of miR-1296 [42].
In this study, we have shown that miR-151 directly targets
several tumor suppressor genes and involved in the progression
and metastasis of PCa. In addition, this is the first report to show
that genistein downregulates miR-151 expression suggesting that
genistein may serve as an important dietary therapeutic agent for
the treatment of PCa.
Materials and Methods
Clinical Prostate Specimens
All tissue slides were reviewed by a board certified pathologist
for the identification of prostate cancer foci as well as adjacent
normal glandular epithelium. All cancer patients had elevated
levels of prostate specific antigen (PSA) and had undergone radical
prostatectomy from 1999 to 2004. The patients’ characteristics are
shown in Table 1. Non-cancerous tissues were obtained from BPH
patients who had undergone prostatectomy or transurethral
resection. Informed consent was obtained from all patients.
Cell Culture
Human prostate cancer cell lines, LNCaP, PC-3 and DU145
and a non-malignant epithelial prostate cell line, RWPE-1, were
purchased from The American Type Culture Collection (Mana-
ssas, VA, USA). The prostate cancer cell lines were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS) in a humidified atmosphere of 5% CO2 and 95% air at
37uC. RWPE-1 cell line was cultured in keratinocyte growth
medium supplemented with 5 ng/mL human recombinant
epidermal growth factor and 0.05 mg/mL bovine pituitary extract
(Invitrogen, Carlsbad, CA, USA). Subconfluent cells (60%-70%
confluent) were treated with genistein (25 mmol/L; Sigma, St
Louis, MO, USA) dissolved in dimethylsulfoxide and cells treated
with vehicle (dimethylsulfoxide) served as control. Cell media and
genistein were changed every day and grown for 4 days.
RNA Extraction
RNA was extracted from FFPE human samples using
a miRNeasy formalin-fixed paraffin-embedded kit (Qiagen,
Valencia, CA, USA) after microdissection. To digest DNA, the
Qiagen RNase-Free DNase kit was used. Total RNA was also
extracted from prostate cancer cell lines and a non-malignant
epithelial prostate cell line using a miRNeasy mini kit (Qiagen)
according to the manufacturer’s instructions.
Quantitative Real-time PCR
Extracted total RNA was reverse transcribed into single-
stranded cDNA using an iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA, USA) and a TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time PCR analysis was performed with an
Applied Biosystems Prism7500 Fast Sequence Detection System
using TaqMan universal PCR master mix according to the
manufacturer’s protocol (Applied Biosystems). Levels of RNA
expression were determined using the 7500 Fast System SDS
software version 1.3.1 (Applied Biosystems). Quantitative PCR
parameters for cycling were as follows: 95uC for 20 seconds, 40
cycles of PCR at 95uC for 3 seconds, and 60uC for 30 seconds. All
reactions were done in a 10-mL reaction volume in triplicate. The
data were analyzed with the delta-delta Ct method to calculate the
fold-change. TaqMan probes and primers for CASZ1 (assay ID:
Figure 5. miR-151a-5p targets CASZ1, IL1RAPL1, SOX17, N4BP1 and ARHGDIA genes. (A) (B) (C) (D) (E) The mRNA levels of five target
genes of miR-151a-5p were determined by quantitative real-time PCR analyses after transfection with miR-151a-5p mimics, miR-151a-5p inhibitor and
negative control in PCa cell lines (PC3 and DU145). (F) The mRNA levels of five target genes of miR-151a-5p were determined by quantitative real-
time PCR analyses after treatment with genistein (25 mM) in PCa cell lines (DU145). (G) The protein levels of target genes of miR-151a-5p were
determined by western blot analyses after transfection with miR-151a-5p mimics, miR-151a-5p inhibitor and negative control in PCa cell lines (PC3
and DU145). Data are presented as the mean 6 SE. *,P,0.05.
doi:10.1371/journal.pone.0043812.g005
Figure 6. Expression of miR-151-5p in PCa specimens. (A) miR-151 expression in clinical samples (BPH, n = 17; PCa, n = 30). **,P,0.0001 (B)
Kaplan-Meier survival curve showing overall survival by miR-151a-5p expression (P = 0.0944).
doi:10.1371/journal.pone.0043812.g006
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Hs00214901_m1), IL1RAPL1 (assay ID: Hs00990788_m1),
SOX17 (assay ID: Hs00751752_s1), N4BP1 (assay ID:
Hs00206373_m1), ARHGDIA (assay ID: Hs00366348), GAPDH
(assay ID: Hs02758991_g1), miR-151a-5p (assay ID: 002642),
miR-151a-3p (assay ID: 002254), RNU48 (Assay ID: 001006)
were obtained from Applied Biosystems. GAPDH and RNU48
were used as internal controls.
Western Blot Analysis
At 72 hours after transfection, cells were lysed with RIPA buffer
(Pierce, Brebieres, France) containing protease inhibitors (Sigma).
Protein quantification was done using a BCA protein assay kit
(Pierce). Protein lysate (30 mg) was separated by 4% to 20% SDS
polyacrylamide gels and transferred to nitrocellulose membrane.
An antibody against SOX17 was purchased from Millipore
(Billerica, MA, USA). Antibodies against ARHGDIA and
GAPDH were purchased from GeneTex (Irvine, CA, USA).
The membrane was washed and then incubated with secondary
antibodies conjugated to horseradish peroxidase (Cell Signaling
Technology, Danvers, MA, USA). Specific complexes were
visualized with an echochemiluminescence (ECL) detection system
(GE Healthcare, Little Chalfont, UK), and the expression level of
these genes was evaluated by using ImageJ software (ver. 1.43;
http://rsbweb.nih.gov/ij/index.html).
Transfection
Pre-miR miRNA precursor and negative control (Applied
Biosystems) were used in the gain-of-function experiments,
whereas Anti-miR miRNA Inhibitor and negative-control (Ap-
plied Biosystems) were used in the loss-of-function experiments.
PC3 and DU145 cells were transiently transfected using
Lipofectamine 2000 transfection reagent (Invitrogen), according
to the manufacturer’s recommendations. Mock transfections, with
the transfection reagent, were used as controls.
Cell Proliferation, Migration, and Invasion Assays
Cell proliferation was measured using a CellTiter 96 AQueous
One Solution Cell Proliferation Assay (MTS) (Promega, Madison,
WI, USA) performed according to the manufacturer’s instructions.
Cell proliferation was determined by absorbance measurements at
490 nm using SpectraMAX 190 (Molecular Devices Co.,
Sunnyvale, CA, USA). Cell migration activity was evaluated by
a wound-healing assay. Cells were plated in six-well dishes, and the
cell monolayers were scraped using a P-20 micropipette tip. The
width of the initial gap (0 h) and the residual gap 24 hours after
wounding were calculated from photomicrographs. A cell invasion
assay was carried out using modified Boyden Chambers consisting
of transwell-precoated Matrigel membrane filter inserts with eight
micron pores in 24-well tissue culture plates (BD Biosciences,
Bedford, MA, USA). Minimum essential medium containing 10%
FBS in the lower chamber served as the chemoattractant, as
described previously [43]. All experiments were performed in
triplicate.
Prediction of MicroRNA Targets
The predicted target genes and their miRNA binding site seed
regions were determined using TargetScan (release 5.2, http://
www.targetscan.org/) and microRNA.org (August 2010 release,
http://www.microrna.org/microrna/home.do). The sequences of
the predicted mature miRNAs were confirmed by miRBase
(release 18.0; http://microrna.sanger.ac.uk/).
Plasmid Construction and Dual-luciferase Reporter
Assays
For 39 UTR luciferase reporter assay, PmirGLO Dual-
Luciferase miRNA Target Expression Vector was used (Promega).
The oligonucleotide sequences (wild-type) used are shown in Table
S1. We also constructed mutated oligonucleotides for each of the
wild-type oligonucleotides (Table S1). In a total volume of 25 ml,
1 ml each of 100 mM forward and reverse oligonucleotide, 2.5 ml
of 10 X annealing buffer (100 mM Tris–HCl, pH 7.5, 1 M NaCl
and 10 mM ethylenediaminetetraacetic acid) and 20.5 ml water
were incubated at 95uC for 3 min and then placed at 37uC for
15 min. The oligonucleotides were ligated into the PmeI–XbaI site
of pmirGLO Dual-Luciferase miRNA Target Expression Vector.
For 39 UTR luciferase assay, prostate cancer cells were co-
transfected with Pre-miR miRNA precursor or Anti-miR miRNA
Inhibitor and pmirGLO Dual-Luciferase miRNA Target Expres-
sion Vectors using Lipofectamine 2000 (Invitrogen) and X-
tremeGENE HP DNA Transfection Reagent (Roche Diagnosis,
Basel, Switzerland, USA) according to the manufacturer’s
instructions. Luciferase reporter assay was performed using the
Dual-Luciferase Reporter Assay System (Promega) 24 hours after
transfection.
Statistical Analysis
The relationship between two variables and the numerical
values obtained by real-time RT-PCR were analyzed using the
nonparametric Mann-Whitney U test or the paired t-test. The
relationship among three variables and the numerical values were
analyzed using the Bonferroni-adjusted Mann-Whitney U test.
Association of miR-151 expression with overall survival was
estimated by the Kaplan–Meier method, and the resulting curves
were compared using the log rank test. All analyses were
performed using Expert StatView (version 4, SAS Institute Inc.,
Cary, NC, USA). In the comparison among three variables, a non-
adjusted statistical level of significance of P,0.05 corresponds to
a Bonferroni-adjusted level of P,0.0167.
Table 1. Prostate cancer patient information.
Characteristic (%)
Age (years)
Median (range) 62 (50–78)
PSA (ng/ml)
Median (range) 5.05 (0.2–298.9)
Total number 30 (100.0)
Gleason Score
GS 6 17 (56.7)
GS 7 10 (33.3)
GS 8 2 (6.7)
GS 9 1 (3.3)
Pathological tumor stage
pT2a 3 (10.0)
pT2b 6 (20.0)
pT2c 11 (36.7)
pT3a 4 (13.3)
pT3b 1 (3.3)
unknown 5 (16.7)
Abbreviations: PSA = prostate-specific antigen; GS =Gleason Score.
doi:10.1371/journal.pone.0043812.t001
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Supporting Information
Table S1 Primer oligonucleotide sequences (wild-type
and mutated).
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